CD44-tropic polymeric nanocarrier for breast cancer targeted rapamycin chemotherapy

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 6, 2014, Pages 1221-1230

  Zhao, Yunqi ^a   Zhang, Ti ^a   Duan, Shaofeng ^a   Davies, Neal M ^b   Forrest, M Laird ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Breast cancer; CD44; Hyaluronic acid; Rapamycin

Indexed keywords

CHEMOTHERAPY; DISEASES; DRUG DELIVERY; NANOPARTICLES; ORGANIC ACIDS;

AREA UNDER THE CURVES; BREAST CANCER; BREAST CANCER MODELS; BREAST CANCER TREATMENT; CD44; DRUG DELIVERY CARRIER; NANOPARTICLE FORMULATION; RAPAMYCIN;

HYALURONIC ACID;

HERMES ANTIGEN; NANOCARRIER; RAPAMYCIN; TEMSIROLIMUS; ANTINEOPLASTIC ANTIBIOTIC; DRUG CARRIER; HYALURONIC ACID; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; RAT; SUSTAINED DRUG RELEASE; THERMAL ANALYSIS; TREATMENT DURATION; TROPISM; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; BREAST; BREAST NEOPLASMS; DRUG EFFECTS; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALIA; MUS; RATTUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD44; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HYALURONIC ACID; MICE, INBRED BALB C; NANOPARTICLES; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS;

EID: 84905268967     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.02.015     Document Type: Article

References (37)

1. Chan J.S., Robertson H.A., Friesen H.G. The purification and characterization of ovine placental lactogen. Endocrinology 1976, 98(1):65-76.
2. Tzircotis G., Thorne R.F., Isacke C.M. Chemotaxis towards hyaluronan is dependent on CD44 expression and modulated by cell type variation in CD44-hyaluronan binding. J Cell Sci 2005, 118(Pt 21):5119-5128.
3. Olsson E., Honeth G., Bendahl P.O., Saal L.H., Gruvberger-Saal S., et al. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 2011, 11:418.
4. Misra S., Heldin P., Hascall V.C., Karamanos N.K., Skandalis S.S., et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 2011, 278(9):1429-1443.
5. Ghosh S.C., Neslihan Alpay S., Klostergaard J. CD44: a validated target for improved delivery of cancer therapeutics. Expert Opin Ther Targets 2012, 16(7):635-650.
6. Peer D., Margalit R. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer 2004, 108(5):780-789.
7. Platt V.M., Szoka F.C. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 2008, 5(4):474-486.
8. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5(3):161-171.
9. Li C., Wallace S. Polymer-drug conjugates: recent development in clinical oncology. Adv Drug Deliv Rev 2008, 60(8):886-898.
10. Shakya A.K., Nandakumar K.S. Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases. J R Soc Interface 2013, 10(79):20120536.
11. Liechty W.B., Kryscio D.R., Slaughter B.V., Peppas N.A. Polymers for drug delivery systems. Annu Rev Chem Biomol Eng 2010, 1:149-173.
12. Pasut G., Veronese F.M. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev 2009, 61(13):1177-1188.
13. Jain A., Jain S.K. PEGylation: an approach for drug delivery. A review. Crit Rev Ther Drug Carrier Syst 2008, 25(5):403-447.
14. Vicent M.J., Dieudonne L., Carbajo R.J., Pineda-Lucena A. Polymer conjugates as therapeutics: future trends, challenges and opportunities. Expert Opin Drug Deliv 2008, 5(5):593-614.
15. Vaidya A., Agarwal A., Jain A., Agrawal R.K., Jain S.K. Bioconjugation of polymers: a novel platform for targeted drug delivery. Curr Pharm Des 2011, 17(11):1108-1125.
16. Du W., Gerald D., Perruzzi C.A., Rodriguez-Waitkus P., Enayati L., et al. Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin. Lab Invest 2013, 93:1115-1127.
17. Ge Y., Chen J. Mammalian target of rapamycin (mTOR) signaling network in skeletal myogenesis. J Biol Chem 2012, 287(52):43928-43935.
18. LoRusso P.M. Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment. Oncology 2013, 84(1):43-56.
19. Chong Z.Z., Shang Y.C., Maiese K. Cardiovascular disease and mTOR signaling. Trends Cardiovasc Med 2011, 21(5):151-155.
20. Kamada Y., Funakoshi T., Shintani T., Nagano K., Ohsumi M., et al. Tor-mediated induction of autophagy via an Apg1 protein kinase complex. J Cell Biol 2000, 150(6):1507-1513.
21. Zhao Y., Sun Y. Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application. Neoplasia 2012, 14(5):360-367.
22. Aoki M., Blazek E., Vogt P.K. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A 2001, 98(1):136-141.
23. Gu J., Ruppen M.E., Cai P. Lipase-catalyzed regioselective esterification of rapamycin: synthesis of temsirolimus (CCI-779). Org Lett 2005, 7(18):3945-3948.
24. Hioki A., Wakasugi A., Kawano K., Hattori Y., Maitani Y. Development of an in vitro drug release assay of PEGylated liposome using bovine serum albumin and high temperature. Biol Pharm Bull 2010, 33(9):1466-1470.
25. Doane T.L., Chuang C.H., Hill R.J., Burda C. Nanoparticle zeta-potentials. Acc Chem Res 2012, 45(3):317-326.
26. Yanez J.A., Forrest M.L., Ohgami Y., Kwon G.S., Davies N.M. Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin. Cancer Chemother Pharmacol 2008, 61(1):133-144.
27. Bagby T.R., Cai S., Duan S., Thati S., Aires D.J., Forrest M.L. Impact of molecular weight on lymphatic drainage of a biopolymer-based imaging agent. Pharmaceutics 2012, 4:276-296.
28. Wolny P.M., Banerji S., Gounou C., Brisson A.R., Day A.J., et al. Analysis of CD44-hyaluronan interactions in an artificial membrane system: insights into the distinct binding properties of high and low molecular weight hyaluronan. J Biol Chem 2010, 285(39):30170-30180.
29. Myckatyn T.M., Ellis R.A., Grand A.G., Sen S.K., Lowe J.B., et al. The effects of rapamycin in murine peripheral nerve isografts and allografts. Plast Reconstr Surg 2002, 109(7):2405-2417.
30. Hussein O., Tiedemann K., Murshed M., Komarova S.V. Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases. Cancer Lett 2012, 314(2):176-184.
31. Lennon F.E., Singleton P.A. Role of hyaluronan and hyaluronan-binding proteins in lung pathobiology. Am J Physiol Lung Cell Mol Physiol 2011, 301(2):L137-L147.
32. Jackson D.G. Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis. APMIS 2004, 112(7-8):526-538.
33. Leung K. Hyaluronan conjugated with IR-783. Molecular Imaging and Contrast Agent Database (MICAD) 2004, Bethesda (MD).
34. Wendt M.K., Molter J., Flask C.A., Schiemann W.P. In vivo dual substrate bioluminescent imaging. J Vis Exp 2011, 56.
35. Dumont F.J., Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci 1996, 58(5):373-395.
36. Kay J.E., Kromwel L., Doe S.E., Denyer M. Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology 1991, 72(4):544-549.
37. Law B.K. Rapamycin: an anti-cancer immunosuppressant?. Crit Rev Oncol Hematol 2005, 56(1):47-60.